The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
about
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cellsAre we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureRole of the tumor microenvironment in mature B-cell lymphoid malignanciesChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaIbrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionMyeloid Cells as Targets for Therapy in Solid TumorsIbrutinib (PCI-32765) in chronic lymphocytic leukemiaBruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibB cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody productionTargeting the Fc receptor in autoimmune diseaseB cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292Small molecules in the treatment of systemic lupus erythematosusNovel agents in mantle cell lymphomaHow will B-cell-receptor-targeted therapies change future CLL therapy?Protein kinase inhibitors against malignant lymphomaTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibSignal transduction in the chronic leukemias: implications for targeted therapiesIbrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinaseMan's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?Developing irreversible inhibitors of the protein kinase cysteinomeNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewIdentification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interactionReversible targeting of noncatalytic cysteines with chemically tuned electrophilesResistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibSecond-generation inhibitors of Bruton tyrosine kinaseNovel Drugs in Follicular LymphomaPembrolizumab in classical Hodgkin's lymphomaManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsCompanion animals: Translational scientist's new best friendsSecondary mutations as mediators of resistance to targeted therapy in leukemiaTargets for Ibrutinib Beyond B Cell MalignanciesCovalent docking of large libraries for the discovery of chemical probesCharacterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress ResponsesA Methyl 4-Oxo-4-phenylbut-2-enoate with in Vivo Activity against MRSA that Inhibits MenB in the Bacterial Menaquinone Biosynthesis PathwayBruton's Tyrosine Kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages
P2860
Q21195261-46268795-AC02-4BD8-B4CD-AF135DDA2192Q24597424-6B9E93A6-A6B1-4644-B5CF-FEE3275854ADQ26738946-DC685476-8925-41B2-BCE8-39977FAEBEEEQ26746934-7BDA9E3F-FFAA-4301-B5A7-5A3DA5A293B7Q26748775-72FC9522-7571-4BCF-8F30-4AC6D3C6FBECQ26764833-FF4BDFC8-F7BA-458F-AAAA-03BD139E932BQ26765624-E088D08A-782E-4A37-ABCC-7014D22ED9D2Q26775506-C4024F75-690C-4411-9616-5913E0516072Q26783430-784DB7DC-0EDB-4C55-BA91-2C802EDAD7BDQ26801832-13F76D83-5639-4157-8B37-B81B2CDD0301Q26852328-4BED085D-538D-429F-AA31-758AF6096380Q26991890-F2CF173F-072A-47ED-8879-49459D8BA0E0Q26995113-A608979A-BF24-42F0-A69B-5022A46949F7Q26996644-9BA244EB-BA50-4D8D-8246-9128B1BE6B82Q27002843-BF381F17-6D4D-414B-A837-935E667F7E7FQ27009550-E43FDBA3-2A32-4E21-B882-35B00ED2A40BQ27010090-28CE4BBE-472B-4F31-897B-40014BDFF23EQ27011763-6C573C00-B4DB-4C65-818D-7C5B37310634Q27024187-AFC5AB50-36DD-47E3-A22D-9A76F88FF021Q27024212-E16D5860-23E5-45C8-9E86-1CCA7A24E4B2Q27025812-3211DDCD-2E2A-4C18-A8B1-EC95D80F9637Q27026031-28A0B4B1-87DF-4F93-BCD0-43A1428CE448Q27026912-9FA8B999-81CB-4A90-85CB-DFEC182590BFQ27027137-8CF545E7-4D04-40D3-96C4-674771CD1E37Q27027983-89256ECD-8C40-449D-9066-2CB61836191DQ27304386-BD51F996-8730-4644-ADFB-E2F807079328Q27674057-9A8E3133-C7AA-4B39-8ADD-45C9CA80AF9EQ27678280-FC6FB863-82C1-4C5A-A2B9-DC4BF7884D6EQ27853011-05FFA6A6-F4C1-4297-A89D-499BA5D30AE3Q28076118-EF84D1D3-7EF7-4321-BBE9-96E35B38A3FBQ28076335-07732A2D-1FD9-412A-839B-B3811ADB84D9Q28079273-9AFD9640-F1D9-49B0-94BE-5CC155B5A2DCQ28081162-465831E8-3F1F-42BC-A765-A195A2353306Q28085490-03DDF92C-9313-4EC8-94AE-5BAF86FE75ACQ28087213-D57F917B-8481-45BE-8EFF-4D7A6B4EF039Q28087772-1A98DCB1-839B-4826-AE0A-613308A7329EQ28250319-029C2F8C-809D-4E3E-9FA0-D3728362A9F6Q28271836-504FFB5E-5536-4B95-9A42-7831A855E7BCQ28396297-3A18062E-6D6B-4C23-8451-F0D3301069CBQ28534361-8EA11654-5ABE-44AF-AD23-BCF7DBADA8BD
P2860
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@ast
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@en
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@nl
type
label
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@ast
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@en
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@nl
prefLabel
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@ast
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@en
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@nl
P2093
P2860
P3181
P356
P1476
The Bruton tyrosine kinase inh ...... disease and B-cell malignancy
@en
P2093
Ashley M Smith
Betty Chang
David Loury
Erik Verner
Joseph J Buggy
Lee A Honigberg
Mint Sirisawad
Richard A Miller
Zhengying Pan
P2860
P304
13075-13080
P3181
P356
10.1073/PNAS.1004594107
P407
P577
2010-07-06T00:00:00Z